(S)-6-{[2-(tert-Butoxycarbonyl-methyl-amino)-ethyl]-[6-(5-chloro-1-methyl-2-pyridin-3-yl-1H-indol-3-yl)-hexanoyl]-amino}-2-((S)-1-carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-hexanoic acid | 1027192-95-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: (S)-6-{[2-(tert-Butoxycarbonyl-methyl-amino)-ethyl]-[6-(5-chloro-1-methyl-2-pyridin-3-yl-1H-indol-3-yl)-hexanoyl]-amino}-2-((S)-1-carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-hexanoic acid
• 英文别名: (2S)-2-[[(3S)-1-(carboxymethyl)-2-oxo-4,5-dihydro-3H-1-benzazepin-3-yl]amino]-6-[6-(5-chloro-1-methyl-2-pyridin-3-ylindol-3-yl)hexanoyl-[2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethyl]amino]hexanoic acid
• CAS: 1027192-95-5
• 化学式: C₄₆H₅₉ClN₆O₈
• 分子量: 859.463
• InChiKey: SJHWSSRBIPZWKO-BCRBLDSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  61
• 可旋转键数：
  22
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  175
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  (S)-6-{[2-(tert-Butoxycarbonyl-methyl-amino)-ethyl]-[6-(5-chloro-1-methyl-2-pyridin-3-yl-1H-indol-3-yl)-hexanoyl]-amino}-2-((S)-1-carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-hexanoic acid 在 三氟乙酸 作用下， 生成 2-<<1-(carboxymethyl)-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl>amino>-6-<<5-<5-chloro-1-methyl-2-(3-pyridinyl)-1H-idol-3-yl>pentanoyl><2-(methylamino)ethyl>amino>hexanoic acid
  参考文献：
  名称：

  Dual Angiotensin Converting Enzyme/Thromboxane Synthase Inhibitors

  摘要：

  A variety of compounds were prepared to determine whether dual angiotensin converting enzyme (ACE)/thromboxane synthase (TxS) inhibition could be obtained in the same molecule. These compounds would be used to explore the concept that a dual inhibitor would have superior antihypertensive activity in the spontaneous hypertensive rat compared to an ACE inhibitor. Potent in vitro dual ACE and TxS inhibition was obtained in the same molecule with five series of compounds. Potent blood pressure lowering in the SHR was observed after oral administration of 8b and 11. However, a correlation between blood pressure lowering and the Al presser response inhibition was not observed. The blood pressure-lowering actions of enalapril were significantly potentiated by concurrent administration of 3, a thromboxane synthase inhibitor. Analysis of the area under the curve for 24 h showed nearly a doubling of the blood pressure-lowering effect.

  DOI：

  10.1021/jm00038a011
• 作为产物：
  描述：

  benzyl (2S)-6-[2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethylamino]-2-[[(3S)-2-oxo-1-(2-oxo-2-phenylmethoxyethyl)-4,5-dihydro-3H-1-benzazepin-3-yl]amino]hexanoate 在 palladium on activated charcoal 氢气 、 三乙胺 、 氯甲酸异丁酯 作用下， 以 乙醇 为溶剂， -10.0~25.0 ℃ 、344.73 kPa 条件下， 反应 5.0h， 生成 (S)-6-{[2-(tert-Butoxycarbonyl-methyl-amino)-ethyl]-[6-(5-chloro-1-methyl-2-pyridin-3-yl-1H-indol-3-yl)-hexanoyl]-amino}-2-((S)-1-carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-hexanoic acid
  参考文献：
  名称：

  Dual Angiotensin Converting Enzyme/Thromboxane Synthase Inhibitors

  摘要：

  A variety of compounds were prepared to determine whether dual angiotensin converting enzyme (ACE)/thromboxane synthase (TxS) inhibition could be obtained in the same molecule. These compounds would be used to explore the concept that a dual inhibitor would have superior antihypertensive activity in the spontaneous hypertensive rat compared to an ACE inhibitor. Potent in vitro dual ACE and TxS inhibition was obtained in the same molecule with five series of compounds. Potent blood pressure lowering in the SHR was observed after oral administration of 8b and 11. However, a correlation between blood pressure lowering and the Al presser response inhibition was not observed. The blood pressure-lowering actions of enalapril were significantly potentiated by concurrent administration of 3, a thromboxane synthase inhibitor. Analysis of the area under the curve for 24 h showed nearly a doubling of the blood pressure-lowering effect.

  DOI：

  10.1021/jm00038a011